

Ivan Pasic

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1242240/publications.pdf>

Version: 2024-02-01

26
papers

326
citations

1163117

8
h-index

888059

17
g-index

26
all docs

26
docs citations

26
times ranked

585
citing authors

#	ARTICLE	IF	CITATIONS
1	Bloodstream Infections and Outcomes Following Allogeneic Hematopoietic Cell Transplantation: A Single-Center Study. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 50.e1-50.e8.	1.2	11
2	Anti-thymocyte globulin and post-transplant cyclophosphamide predisposes to inferior outcome when using cryopreserved stem cell grafts. <i>European Journal of Haematology</i> , 2022, 108, 61-72.	2.2	9
3	Allogeneic hematopoietic stem cell transplantation in patients with therapy-related hematologic malignancies developing after multiple myeloma. <i>European Journal of Haematology</i> , 2022, 108, 430-436.	2.2	2
4	Improving Safety and Outcomes After Allogeneic Hematopoietic Cell Transplantation: A Single-Center Experience. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 265.e1-265.e9.	1.2	6
5	Chronic kidney disease, survival and graft-versus-host-disease-free/relapse-free survival in recipients of allogeneic hematopoietic stem cell transplant. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 1583-1592.	2.9	2
6	Anti-thymocyte Globulin and Post-transplant Cyclophosphamide do not abrogate the inferior outcome risk conferred by human leukocyte antigen-A and -B mismatched donors. <i>European Journal of Haematology</i> , 2022, 108, 288-297.	2.2	4
7	The 17-gene stemness score associates with relapse risk and long-term outcomes following allogeneic haematopoietic cell transplantation in acute myeloid leukaemia. <i>EJHaem</i> , 2022, 3, 873-884.	1.0	2
8	Acute kidney injury within 100 days post allogeneic hematopoietic cell transplantation is associated with increased risk of post-transplant complications and poor transplant outcomes. <i>Bone Marrow Transplantation</i> , 2022, 57, 1411-1420.	2.4	6
9	Pilot prospective study of Frailty and Functionality in routine clinical assessment in allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 60-69.	2.4	26
10	Clinical prevalence and outcome of cardiovascular events in the first 100 days postallogeneic hematopoietic stem cell transplant. <i>European Journal of Haematology</i> , 2021, 106, 32-39.	2.2	16
11	Prolactin, a potential biomarker for chronic GVHD activity. <i>European Journal of Haematology</i> , 2021, 106, 158-164.	2.2	2
12	Subcutaneous immunoglobulin in allogeneic hematopoietic cell transplant patients: A prospective study of feasibility, safety, and healthcare resource use. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2021, 14, 302-310.	0.9	4
13	Moderate-severe grade of chronic graft versus host disease and younger age (less than 45 years old) are risk factors for avascular necrosis in adult patients undergoing allogeneic hematopoietic cell transplantation. <i>Annals of Hematology</i> , 2021, 100, 1311-1319.	1.8	2
14	Prognostic impact of the adverse molecular-genetic profile on long-term outcomes following allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2021, 56, 1908-1918.	2.4	10
15	Inferior outcomes with reduced intensity conditioning followed by allogeneic hematopoietic cell transplantation in fit individuals with acute lymphoblastic leukemia: a Canadian single-center study and a comparison to registry data. <i>Leukemia and Lymphoma</i> , 2021, 62, 2193-2201.	1.3	5
16	Experience Using Anti-Thymocyte Globulin With Post-Transplantation Cyclophosphamide for Graft-Versus-Host Disease Prophylaxis in Peripheral Blood Haploidentical Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 428.e1-428.e9.	1.2	11
17	Pretransplant bone marrow cellularity and blood count recovery are not associated with relapse or survival risk following allogeneic stem cell transplant for AML in CR. <i>European Journal of Haematology</i> , 2021, 107, 354-363.	2.2	1
18	Lower dose of ATG combined with post-transplant cyclophosphamide for HLA matched RIC alloHCT is associated with effective control of GVHD and less viral infections. <i>Leukemia and Lymphoma</i> , 2021, 62, 3373-3383.	1.3	12

#	ARTICLE	IF	CITATIONS
19	Refined hepatic grading system in chronic graft-versus-host disease improves prognostic risk stratification of long-term outcomes. <i>European Journal of Haematology</i> , 2021, 106, 508-519.	2.2	1
20	Outcomes of patients diagnosed with chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation: Results from a tertiary care center. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2021, , .	0.9	0
21	Post-transplant cyclophosphamide combined with anti-thymocyte globulin for graft-vs-host disease prophylaxis improves survival and lowers non-relapse mortality in older patients undergoing allogeneic hematopoietic cell transplantation. <i>Annals of Hematology</i> , 2020, 99, 1377-1387.	1.8	15
22	Less Is More: Superior Graft-versus-Host Disease-Free/Relapse-Free Survival with Reduced-Intensity Conditioning and Dual T Cell Depletion in Acute Myelogenous Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1511-1519.	2.0	6
23	Incidence, Outcomes and Predictors of Acute Kidney Injury Post Allogeneic Stem Cell Transplant. <i>Blood</i> , 2020, 136, 16-17.	1.4	5
24	Influence of <i>FLT3-ITD</i> and <i>NPM1</i> status on allogeneic hematopoietic cell transplant outcomes in patients with cytogenetically normal AML. <i>European Journal of Haematology</i> , 2019, 102, 368-374.	2.2	6
25	Two <i>BRM</i> promoter polymorphisms predict poor survival in patients with hepatocellular carcinoma. <i>Molecular Carcinogenesis</i> , 2018, 57, 106-113.	2.7	10
26	Recurrent Focal Copy-Number Changes and Loss of Heterozygosity Implicate Two Noncoding RNAs and One Tumor Suppressor Gene at Chromosome 3q13.31 in Osteosarcoma. <i>Cancer Research</i> , 2010, 70, 160-171.	0.9	152